FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
SYFOVRE slowed GA progression with increasing effects over time A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) […]
